TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perceptions of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Wolf Motor Function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Fluid ≥ 3.5mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for rescue thrombolysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healthy Relationship Knowledge and Skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risky Sexual Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lipid panel concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anxiety assessment using the Beck scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early liver regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for ICU admission
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Achieving a Clinically Relevant Response in Physician Global Assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of oral CB-5083
Endpoint domain: Adverse events/effects
Primary endpoint: Restoration of Full-length Type VII Collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anchoring Fibrils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient knowledge about rheumatoid arthritis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage with POP-Q point C equal to or less than -5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in point C and D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Colony Forming Units (Stage 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Colony Forming Units (Stage 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Colony Forming Units (Stage 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-pneumococcal Antibody Concentrations >= 0.20 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urine albumin/creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of triple site CRT
Endpoint domain: Adverse events/effects
Primary endpoint: EMG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of laboratory value of endothelial inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of flow-mediated dilation (FMD) of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy (CR + PR Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Viral Rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic performance of antibody index for neurosyphilis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CPAP compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mild cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Frequency and Severity of CDC-based CFS Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in a Single Composite Product of Average Frequency and Severity Scores of CDC-based CFS Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Who Are Compliant With Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time taken off from work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence and penetrance of BRCA1 and BRCA2 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline intestinal epithelial barrier biomarker profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Scale for the Assessment of Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Clinical Global Impression Severity of Symptoms Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Brief Psychiatric Rating Scale-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Returning to Care Following Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: procedural compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in submaximal exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total COPD Exacerbation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of PRO044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of PRO044
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Number of Medications Taken for Fibromyalgia (FM) Over 12 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective and subjective responses measured by CDQ-24 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Epileptiform activity during REM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local tumour Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bacterial species concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frontal cortical activities during cognitive test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in urine levels of NTX (uNTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in bone-alkaline phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with RVNA titer ≥ 0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in diabetic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in peripheral and sympathic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative Predictive Value (NPV) for ruling out GG2+ prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: patient satisfaction 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient satisfaction 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Piperacillin Concentration Maintained at a Level Four Times Above the MIC 50% of the Dosing Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for Phenylephrine HCl 30 mg Extended Release Tablets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of MGC imaging and the gamma probe in identifying SLNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of agreement of hot spot detection between FGC and MGC imaging systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of the time required to use the MGC imaging system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cytokine levels in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the occurrence of Eating disorder diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 48 in Osteoid Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Change From Baseline to Week 48 in Osteoid Surface/Bone Surface (OS/BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Change From Baseline to Week 48 in Osteoid Volume/Bone Volume (OV/BV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Change From Baseline to Week 48 in Mineralization Lag Time (MLt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Changes in inflammation measured via tumor necrosis factor alpha (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in inflammation measured via erythrocyte sedimentation rate (mm/hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in inflammation measured via c-reactive protein (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in glucose regulation assessed via plasma glucose (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in glucose regulation assessed via insulin (mIU/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Realization of patient-defined objectives
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: treatment adherence rate (TAR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of good quality blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of GSDMD, NF-kB and miR-379-5p
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep N2 phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Percentage of Correctly Identified Positive (Dysplastic) Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Correctly Identified Negative (Non-Dysplastic) Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Achieving vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: PaO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of intrapulmonary shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Bioavailability (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Percentage of Total Radioactivity Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Percentage of Total Radioactivity Excreted in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-related Fear and Avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peripheral blood saturation (SpO2) before application of LFNO or HFNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood saturation (SpO2) 15 minutes after institution of LFNO or HFNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood saturation (SpO2) 5 minutes after discontinuing analgo-sedation and oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Stroke Work
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic and diastolic blood pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activity of novel DNA repair inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hsp90α Concentration (ng/ml) of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hematopoietic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cord blood engraftment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma Vitamin E Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of 68Ga PSMA PET scans for detection of tumor location (per-patient basis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of 68Ga PSMA PET scans for detection of tumor location (per-region basis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of sepsis-induced thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cystic Fibrosis-specific HRQoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients With ADA
Endpoint domain: Adverse events/effects
Primary endpoint: Activity of Daily Living (ADL) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Use of primary healthcare resources 4 years after baseline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Repetitive Behavior Scale (RBS_SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain intensity-rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain intensity-activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude Rate of Newly Diagnosed Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diameter of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean absolute relative deviation (MARD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atelectatic area on Chest CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urodynamic stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of correctly assessed ECG signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of fixation and regression during reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Lipid/lipoprotein change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour ambulatory blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow-mediated dilation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade 3 hand foot syndrome (rate)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of coronary CT angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Follicular fluid CoQ10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulus cells function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum inspiratory muscle pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: distance covered in six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Medical Research Council (mMRC) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortical Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum LC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prokalsitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exenatide associated adverse event occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the exenatide concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Penalties Adjusted Composite Efficacy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Well-controlled Asthma Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumer Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in scores on Scale for Suicide Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: conversion to tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax of Dosing Regimen A vs. Dosing Regimen B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCs of Dosing Regimen A vs. Dosing Regimen B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health-Related Quality of Life related to hand function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in six-minute walk distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of initial hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very early rebleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Ulcer bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who develop febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Ascites Symptom Inventory (ASI-7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbiological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peak vertical ground reaction plantar force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in the microbiome population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shivering response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GA progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Classification of Wound Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Kappa coefficient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in fatigue severity scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: FFI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life